Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. He was joined in 1999 by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Sapacitabine, Cyclacel’s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.
Cyclacel’s corporate headquarters are in Berkeley Heights, New Jersey, where the business development and medical and regulatory functions are also located. The company's primary research facility is located in Dundee, Scotland. Dundee is the main location of our translational research and preclinical activities. Grants received from the UK Governments Biomedical Catalyst will fund the development of two programmes; CYC065, a cyclin dependent kinase inhibitor, in pre-IND stage and CYC140, a polo-like kinase inhibitor in preclinical stage.
Please visit www.cyclacel.com for additional information.